Cencora Corp Lobbying Update: $50k Disclosed for Q4 2024

Cencora Corp (formerly AmerisourceBergen) has disclosed $50,000 in lobbying efforts for Q4 2024, focusing on key healthcare issues. This may influence investor sentiment amidst concerns over drug pricing and access.

Date: 06-01-2025

AI Rating: 4

Key Developments in Cencora Corp's Lobbying Efforts

Cencora Corp has reported significant lobbying expenditures totaling $50,000 in Q4 2024. The lobbying focus includes critical issues such as Medicare reimbursement, drug pricing, and drug shortages, which are prominent topics influencing healthcare policy.

Additionally, insider trading activity shows an alarming trend where insiders have exclusively sold $COR stock without any purchases. Notably, high-profile executives have been selling shares, with over 136,000 shares sold by Executive Chairman Steven H. Collis and massive sells from Walgreens Boots Alliance, indicating a lack of confidence or negative outlook among insiders.

Institutional Investor Activity

The data shows a mixed reaction from institutional investors, with 560 adding shares while 470 decreased their positions recently. The sizeable sell-off by Walgreens Boots Alliance (removing 4.4 million shares) and Bank of America (-1.8 million shares) raises concerns about the company's stability and future prospects. On the flip side, Pacer Advisors has dramatically increased its stake, but overall, the sell-offs outweigh the adds, which can be interpreted as a bearish signal.

Stocks: CENC WBA BAC